The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | ELCC 2025 highlights: MARIPOSA, COCOON, LAURA, and more
Umit Tapan, MD, Boston University Medical Center, Boston, MA, gives an overview of trials presented at the 2025 European Lung Cancer Congress (ELCC), including the MARIPOSA (NCT04487080) and COCOON (NCT06120140) trials, which evaluated amivantamab with lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC). Dr Tapan additionally highlights the KRYSTAL-7 trial (NCT04613596) of first-line adagrasib with pembrolizumab in KRAS G12C-mutated NSCLC, updated overall survival results from the LAURA study (NCT03521154) of osimertinib in EGFR-mutant NSCLC, as well as the ADRIATIC trial (NCT03703297) of durvalumab in limited-stage small-cell lung cancer. This interview took place at ELCC 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
